A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.
How Do Patients With Myeloproliferative Neoplasms Fare After COVID-19 Infection?
Two analyses from the MPN-COVID study from a group of researchers led by Tiziano Barbui, MD, of the United Hospitals of Bergamo in Italy,...
Is Pretransplant Disease Reduction Necessary in MDS and AML?
For patients with myelodysplastic syndromes (MDS) or low-blast secondary acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (AHCT) is the only potentially curative treatment...
HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival Outcomes in MDS
Transplantation with an HLA-haploidentical relative donor is associated with similar two-year survival rates compared with transplantation with a matched unrelated donor in patients with...
Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS
For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
Venetoclax and Azacitidine Combination Associated With Durable Responses in Higher-Risk MDS
More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented...
Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms
Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection
Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS
Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with...
Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS
Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients...
Machine Learning Detects Prognostic Associations Between Morphologic and Genetic Changes in MDS
A new artificial intelligence–based technique was able to establish correlations between genetic and morphologic biomarkers, revealing diagnostically and prognostically important relationships, according to results...
